EU IMI and US Critical Path avoid duplication
This article was originally published in Scrip
The EU Innovative Medicines Initiative has signed a memorandum of understanding with the Critical Path Institute (C-Path) in the US to further the shared objective the two public-private organisations have of accelerating the development of safer, more effective medicines.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.
A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule.
The UK regulator is expecting a rise in amendments and deviations to ongoing clinical investigations of medical devices due to the COVID-19 pandemic and has issued advice on how companies should manage these.